DaVita stock (US23918K1088): TD Cowen raises price target after Q1 earnings

DaVita shares trade near 52-week highs following strong Q1 results with 6% revenue growth. TD Cowen lifted its price target to $201 from $144 on May 11, maintaining a Hold rating.

DaVita released its fiscal year 2026 first-quarter earnings on May 5, reporting revenue growth of 6% year-over-year to $3.42 billion, which drove shares up 23.5% in the subsequent trading session, Barchart as of May 2026. On May 11, TD Cowen raised its price target on the stock to $201 from $144 while keeping a Hold rating, Barchart as of May 2026. The stock traded at $198.10 on May 13, down 1.22% from $200.54, StockInvest.us as of May 13, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: DaVita Inc.
• Sector/industry: Healthcare / Dialysis Services
• Headquarters/country: United States
• Core markets: US dialysis clinics
• Key revenue drivers: Kidney care treatments
• Home exchange/listing venue: NYSE (DVA)
• Trading currency: USD

DaVita: core business model

DaVita operates a network of dialysis centers primarily in the United States, providing treatment for patients with chronic kidney failure. The company manages over 2,600 outpatient dialysis centers serving approximately 200,000 patients as of recent reports. Its integrated kidney care model includes clinic operations, physician services, and pharmacy support, positioning it as a leader in end-stage renal disease care for US investors tracking healthcare services.

Main revenue and product drivers for DaVita

DaVita's revenue stems mainly from dialysis treatments reimbursed by government programs like Medicare and Medicaid, which account for the majority of US patients. In Q1 FY2026 reported on May 5, revenue reached $3.42 billion, up 6% from the prior year, driven by patient volume growth and treatment efficiency, Barchart as of May 2026. Key drivers include core dialysis services and ancillary offerings like home dialysis and vascular access care.

Industry trends and competitive position

The US dialysis market is dominated by DaVita and Fresenius Medical Care, with DaVita holding about 37% market share. Trends include a shift toward value-based care and home dialysis expansion amid rising chronic kidney disease prevalence linked to diabetes and hypertension. DaVita's scale provides leverage in payer negotiations, relevant for US investors as Medicare policies impact profitability.

Why DaVita matters for US investors

DaVita's exposure to the US healthcare system, particularly Medicare-funded dialysis, ties its performance to domestic policy and demographics. With shares at $198.10 market cap of $12.72 billion and P/E of 19.25 as of May 13, it offers a play on aging population trends, Robinhood as of May 2026.

Conclusion

DaVita's recent Q1 earnings beat and analyst price target upgrade highlight operational strength amid favorable industry tailwinds. Shares remain volatile near highs, with insider sales noted as COO David Maughan sold shares worth $4.09 million on May 11-12, Investing.com as of May 2026. Investors monitor reimbursement rates and volume growth for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.